Immunotherapy

Article	Citations
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors	167
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings	70
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens	66
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait	61
A global picture: therapeutic perspectives for COVID-19	53
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis	35
Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma	34
Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?	34
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report	31
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins	28
Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i)	27
Interferons: role in cancer therapy	26
Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis	26
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma	26
Systemic immune–inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis	24
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia	24
Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma	24
Immunotherapy for gastric cancer: a 2021 update	24
The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy	23
TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases	22
Tumor cell-based vaccine: an effective strategy for eradication of cancer cells	22
Therapeutics to tackle Omicron outbreak	22
Antimicrobial/anticancer peptides: bioactive molecules and therapeutic agents	22
Concurrent Vogt–Koyanagi–Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma	21
Sublingual immunotherapy for food allergy and its future directions	21

Efficacy of immune checkpoint inhibitors and age in cancer patients	20
Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer	19
Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy	19
Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?	19
Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection	19
COVID-19: the use of immunotherapy in metastatic lung cancer	18
Targeted allergen-specific immunotherapy within the skin improves allergen delivery to induce desensitization to peanut	18
Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function	17
Atherosclerosis: immunopathogenesis and strategies for immunotherapy	16
Obesity, COVID-19 and immunotherapy: the complex relationship!	16
Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment	16
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019	16
Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations	16
Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma	16
The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease	16
PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare	15
Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment	15
Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report	15
Non-coding RNA and immune-checkpoint inhibitors: friends or foes?	15
Immunity to glycan α-Gal and possibilities for the control of COVID-19	15
Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward	15
Cost–effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC	15
Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy	15
Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma	15
Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy	14
Early change in peripheral CD4+ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer	14
Romosozumab in the treatment of osteoporosis	13
Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature	13
MUC1 antibody-based therapeutics: the promise of cancer immunotherapy	13
Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis	13
Efficacy of immunotherapy inKRAS-mutant non-small-cell lung cancer with comutations	13
Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer	13
Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy	12
Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment	12
Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19	12
Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis	12
Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer	12
Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application	12
Emerging advances in cationic liposomal cancer nanovaccines: opportunities and challenges	12
Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report	12
Immunotherapy in hematological malignancies: recent advances and open questions	11
Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review	11
Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases	11
Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems	11
A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review	11
Guselkumab in the treatment of moderate-to-severe plaque psoriasis	11
Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination	11
Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma	11
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy	11
Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer	11

Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR	10
Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis	10
Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report	10
Immunotherapy in psoriasis	10
A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma	10
The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases	10
A review of secukinumab in psoriasis treatment	10
Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study	10
Immunotherapy for cholangiocarcinoma: a 2021 update	10
Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma	10
Dupilumab use in atopic dermatitis and beyond in skin diseases	9
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison	9
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases	9
Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma	9
Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis	9
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients	9
Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy	9
The immunotherapy revolution in genitourinary malignancies	9
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases	9
Neurological adverse events following CAR T-cell therapy: a real-world analysis	9
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)	9
COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy	9
Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors	8
Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers	8
Asthma immunotherapy and treatment approaches with mesenchymal stem cells	8
Differences between diffuse idiopathic skeletal hyperostosis and spondyloarthritis	8
PD-1,CTLA4,PD-L1andPD-L2DNA methylation in papillary thyroid carcinoma	8
Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma	8
Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China	8
Obesity and immunotherapy: the surprisingly positive association!	8
Durable response to combination radiotherapy and immunotherapy in EP-resistant lung large-cell neuroendocrine carcinoma with B2M and STK11 mutations: a case report	8
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice	7
Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up	7
Exploiting antibody biology for the treatment of cancer	7
Eculizumab in the treatment of neuromyelitis optica spectrum disorder	7
Hurdles for the wide implementation of photoimmunotherapy	7
Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians	7
Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report	7
Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review	7
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review	7
Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity	7
Immunoregulatory T cell epitope peptides for the treatment of allergic disease	7
Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+T cells in lung cancer	7
Cost–effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer	7
Immunology of osteoporosis: relevance of inflammatory targets for the development of novel interventions	7
Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma	7
Pembrolizumab-associated erythema nodosum in the treatment of metastatic melanoma	7
Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1	7
Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy	7
Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer	7
Treatment of EAE mice with Treg, G-MDSC and IL-2: a new insight into cell therapy for multiple sclerosis	7
Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis	7
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence	7
Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy	7
HLA loss of heterozygosity-mediated discordant responses to immune checkpoint blockade in squamous cell lung cancer with renal metastasis	7
Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature	7
Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research	6
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary	6
Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma	6
Small-cell breast carcinoma with response to atezolizumab: a case report	6
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland	6
Severe chronic nonlichenoid oral mucositis in pembrolizumab-treated patients: new cases and a review of the literature	6
Designing novel immunocombinations in metastatic renal cell carcinoma	6
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab	6
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy	6
Peptide vaccine with glucopyranosyl lipid A–stable oil-in-water emulsion for patients with resected melanoma	6
Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases	6
Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review	6
Delayed immune-related neutropenia with hepatitis by pembrolizumab	6
Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis	6
Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review	6
GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey	6
Lichenoid drug eruption on the lower lip caused by anti-PD-1 monoclonal antibody: a case report and literature review	6
Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer	6
The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't	6
Therapeutic cancer vaccine therapy for acute myeloid leukemia	6
Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review	6
The effect of low-dose chemotherapy on the tumor microenvironment and its antitumor activity combined with anti-PD-1 antibody	5
Immune checkpoint inhibitors and corneal transplant rejection: a call for awareness	5
Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review	5

Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib	5
Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade	5
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis	5
A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis	5
Adoptive Treg cell-based immunotherapy: Frontier therapeutic aspects in rheumatoid arthritis	5
Long-term immune-related adverse events after discontinuation of immunotherapy	5
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis	5
Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report	5
Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors	5
Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?	5
Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a case report	5
Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy	5
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer	5
BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma	5
Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report	5
Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors	5
Cost–effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma	5
Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient	5
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors	5
Plasmodium falciparum-infected humanized mice: a viable preclinical tool	5
Appropriate use of antimicrobial therapy for COVID-19 co-infection	5
IL-13 antagonists in the treatment of atopic dermatitis	5
Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer	4
A new perspective on the potential application of RIPK1 in the treatment of sepsis	4
COVID-19 and the newly rediscovered multidisciplinarity	4
Targeting the tumor microenvironment of Ewing sarcoma	4
Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review	4
Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy	4
Urothelial carcinoma in the era of immune checkpoint inhibitors	4
Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies	4
Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review	4
A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor	4
Potential biomarkers and resistance mechanisms of atezolizumab in a patient with lung squamous cell carcinoma	4
How bilastine is used to treat allergic rhinitis and urticaria in children	4
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report	4
Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case report	4
Antibody therapy against antibiotic-resistant diarrheagenic Escherichia coli: a systematic review	4
Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma	4
Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma	4
Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report	4
Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy	4
Safety and effectiveness of the 300 IR sublingual house dust mite allergen immunotherapy tablet: 2-year interim analysis of a specified drug-use survey	4
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology	4
Nimotuzumab for COVID-19: case series	4
The latest developments in biomarkers predicting response to immunotherapy	4
Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics	4
The characteristic of tumor immune microenvironment in pulmonary carcinosarcoma	4
Upadacitinib for moderate to severe atopic dermatitis	4
Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm])	4
Etrasimod for the treatment of ulcerative colitis	4
Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers	4
Use of upadacitinib in the treatment of psoriatic arthritis	4
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)	4
miRNA profiles change during grass pollen immunotherapy irrespective of clinical outcome	4
Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy	4
Small-molecule-based immunotherapy for immunologically mediated skin conditions	4
Abscopal effect of radiation therapy and nivolumab in a patient with combined small-cell lung cancer: a case report	4
Three decades of clinical trials on immunotherapy for human leishmaniases: a systematic review and meta-analysis	4
Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis	4
Mesenchymal stem cells derived from human dental follicle modulate the aberrant immune response in atopic dermatitis	3
Safety and effectiveness of a microcrystalline tyrosine-associated mite extract immunotherapy for allergic rhinitis	3
Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?	3
Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature	3
Immunotherapeutic approach for advanced pancreatic adenocarcinoma	3
So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis	3
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis	3
Add-on or alone? Inhaled nebulized immunoglobulin reduces upper airway infections: 24 months of real-life experience	3
Safety and efficacy of mutant neoantigen-specific T-cell treatment combined anti-PD-1 therapy in stage IV solid tumors	3
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations	3
Under-prescription of allergen-immunotherapy: why is it important to prescribe it in childhood instead?	3
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis	3
Cost–effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma	3
Indications and effects of biological agents in the treatment of noninfectious uveitis	3
Omalizumab and adalimumab: a winning couple	3
Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?	3
Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer	3
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature	3
Uveitis associated with cancer immunotherapy: long-term outcomes	3
PD-1 blockade for disseminated Kaposi sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia	3
Checkpoint inhibitors in BCG-unresponsive nonmuscle invasive bladder cancer: can they help spare the bladder?	3
Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis	3
Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis	3
Harnessing gene fusion-derived neoantigens for ‘cold’ breast and prostate tumor immunotherapy	3
Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report	3
Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor	3
Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA	3
Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer	3
An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases	3
Combining in situ vaccination and immunogenic apoptosis to treat cancer	3
Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects	3
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review	3
Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis	3
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination	3
Pembrolizumab-induced follicular eruption and response to isotretinoin	3
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib	3